IPERION (IPR) H1 2026 earnings summary

Executive summary

• Net loss attributable to shareholders for the six months ended 30 September 2025 was $158,254, a significant improvement from a net loss of $363,730 in the same period last year, mainly due to a discount on outsourced manufacturing fees.

• No sales income was recorded during the period.

• Product development focused on Pathoglaze-infused polymer jute bags for cocoa and coffee shipping, in collaboration with a multinational chocolate manufacturer.

Financial highlights

• Net loss for the period was $158,254, compared to $363,730 in the prior year period.

• Administrative expenses decreased by $10,435 year-over-year.

• Cash and cash equivalents at 30 September 2025 were $241,882, down from $425,341 at 31 March 2025.

• Net cash outflow from operating activities was $183,459 for the six months ended 30 September 2025.

Outlook and guidance

• Ongoing R&D aims to expand Pathoglaze applications and market potential.

• Updates on material developments will be provided as they arise.